Sigma Planning Corp Has $2.59 Million Position in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Sigma Planning Corp trimmed its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 2.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,741 shares of the biotechnology company’s stock after selling 485 shares during the period. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $2,591,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Cornerstone Advisors Inc. raised its position in shares of Sarepta Therapeutics by 71.0% during the 4th quarter. Cornerstone Advisors Inc. now owns 265 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC purchased a new position in shares of Sarepta Therapeutics in the first quarter worth approximately $35,000. Quad Cities Investment Group LLC increased its position in shares of Sarepta Therapeutics by 100.0% in the first quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 200 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $51,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Sarepta Therapeutics in the first quarter worth approximately $51,000.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the sale, the director now owns 21,717 shares of the company’s stock, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.60% of the stock is owned by corporate insiders.

Shares of SRPT stock traded down $4.59 during mid-day trading on Wednesday, reaching $118.12. The company’s stock had a trading volume of 732,243 shares, compared to its average volume of 1,224,752. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. Sarepta Therapeutics Inc has a 1-year low of $90.00 and a 1-year high of $176.50. The stock has a market cap of $8.96 billion, a price-to-earnings ratio of -21.63 and a beta of 1.98.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The business had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. On average, sell-side analysts predict that Sarepta Therapeutics Inc will post -4.33 earnings per share for the current year.

Several research firms have recently weighed in on SRPT. Zacks Investment Research raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 13th. BidaskClub downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 22nd. ValuEngine raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 9th. Evercore ISI began coverage on shares of Sarepta Therapeutics in a research report on Thursday, April 11th. They set an “outperform” rating and a $175.00 price objective on the stock. Finally, BTIG Research set a $190.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a hold rating, twenty-six have given a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus target price of $199.35.

ILLEGAL ACTIVITY WARNING: “Sigma Planning Corp Has $2.59 Million Position in Sarepta Therapeutics Inc (NASDAQ:SRPT)” was published by Sundance Herald and is the property of of Sundance Herald. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://sundanceherald.com/2019/05/29/sarepta-therapeutics-inc-srpt-shares-sold-by-sigma-planning-corp.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: What Factors Can Affect Return on Equity?

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply